GlassScriptPhysician profile
Maciej Solarewicz
NPI 1093792574
$2,093.68
in general payments reported to CMS, 2019-2025
14 companies · $96.36 in 2025
The $96.36 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $178 · 2021: $490 · 2022: $186 · 2023: $414 · 2024: $340 · 2025: $96.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $546.84 | 2023-2025 | Nuedexta, Rexulti |
| Sun Pharmaceutical Industries INC. | $395.17 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $344.70 | 2019-2024 | Austedo Xr |
| Sumitomo Pharma America, INC. | $135.84 | 2023 | Gemtesa, Aptiom |
| Acadia Pharmaceuticals INC | $119.06 | 2021 | |
| Sunovion Pharmaceuticals INC. | $106.88 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $94.00 | 2024 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.77 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.40 | 2021-2023 | |
| Lilly USA, LLC | $60.13 | 2019-2022 | |
| Novo Nordisk INC | $53.96 | 2019 | |
| Avanir Pharmaceuticals, INC. | $41.56 | 2020-2022 | |
| Pfizer INC. | $25.62 | 2019 | |
| Xeris Pharmaceuticals, INC. | $16.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maciej Solarewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.